Publications

Filter by year

Filter by type

Filter by year

Showing all years

Vitiligo - a disease: A position paper on stigmatization, life quality impairment and psychosocial comorbidity

M. Böhm, R. Sommer, U. Gieler, P. Staubach, A. Zink, C. Apfelbacher & E.M.J. Peters

Vitiligo is a common disorder characterized by the visible loss of skin pigmentation. Non-segmental vitiligo (NSV) is the major subtype. The disease is caused by autoimmune-mediated destruction of melanocytes. Vitiligo leads to stigmatization and a significant reduction in quality of life. We recommend optimizing care by incorporating the assessment of quality of life as a standard in routine care, in addition to monitoring disease activity.

PMID:
39167551
DOI:
https://doi.org/10.1111/ddg.15503

Effectiveness of tildrakizumab for itch, pain, and fatigue in patients with moderate-to-severe psoriasis: 52-week results from the real-world POSITIVE study

U. Mrowietz, M. Augustin, Z. Reguiai, S. Gerdes, E. Daudén, W. Weger, J.T. Maul, P. Laws, L. Naldi, P.D. Ghislain, E. de Jong, S. Mburu, V. Koscielny, E. Massana, I. Kasujee & R. Sommer

Poster presented at the 33rd EADV Congress, Amsterdam, the Netherlands

Effectiveness of tildrakizumab in patients with moderate-to-severe psoriasis located in special areas: 52-week results from the POSITIVE study

M. Augustin, R. Sommer, Z. Reguiai, S. Gerdes, E. Daudén, W. Weger, J.T. Maul, P. Laws, L. Naldi, P.D. Ghislain, E. de Jong, S. Mburu, V. Koscielny, E. Massana, I. Kasujee & U. Mrowietz

Poster presented at the 33rd EADV Congress, Amsterdam, the Netherlands

Quality of Life in Infants and Toddlers with Dermatological Conditions – Validation of the German Version of the InToDermQoL Questionnaire

J. Traxler, N. da Silva-Burger, M. Augustin, H. Ott, S. Hoffmann, R. Fölster-Holst, M. Baumeister, P. Staubach & R. Sommer

Poster presentation presented at the 31st Annual Conference of ISOQOL, Cologne, Germany

Impact of patient psoriasis on partner well-being in a real-world setting: 52-week interim data of the phase IV POSITIVE study

U. Mrowietz, R. Sommer, Z. Reguiai, S. Gerdes, E. Daudén, W. Weger, J.T. Maul, P. Laws, L. Naldi, P.D. Ghislain, E. de Jong, S. Mburu, V. Koscielny, E. Massana, I. Kasujee & M. Augustin

Poster presented at the 33rd EADV Congress, Amsterdam, the Netherlands

High effectiveness of tildrakizumab regardless of baseline characteristics in patients with moderate-to-severe psoriasis: 52-week results from the POSITIVE study

U. Mrowietz, R. Sommer, Z. Reguiai, S. Gerdes, E. Daudén, W. Weger, J.T. Maul, P. Laws, L. Naldi, P.D. Ghislain, E. de Jong, S. Mburu, V. Koscielny, E. Massana, I. Kasujee & M. Augustin

Poster presented at the 33rd EADV Congress, Amsterdam, the Netherlands

Breaking Barriers: Randomized Controlled Trials Assessing an Intervention to Combat Stigma in Chronic Skin Disease

J. Traxler, C.C. Braren-von Stülpnagel, M. Augustin, M. Grosser & R. Sommer

Oral presentation presented at the 10th Appearance Matters Conference, Bristol, UK

DEVISE – Entwicklung und Evaluation einer Online-Intervention zur Reduktion von Selbststigmatisierung bei Menschen mit sichtbaren chronischen Hauterkrankungen

J. Traxler, C.F.Z. Stuhlmann, N. da Silva-Burger, C. Stierle, M. Rudnik & R. Sommer

Oral presentation presented at the 23rd DKVF Conference, Potsdam, Germany

Reducing self-stigma in chronic skin disease - Development and pilot-test of the HautKompass online programme

J. Traxler, C.F.Z. Stuhlmann, N. da Silva-Burger, C. Stierle, M. Rudnik & R. Sommer

Oral presentation presented at the European Health Psychology Society Conference (EHPS), Cascais, Portugal

Patient-reported well-being using tildrakizumab in a real-world setting: 52-week interim data of the phase IV POSITIVE study

R. Sommer, M. Augustin, Z. Reguiai, S. Gerdes, E. Daudén, W. Weger, J.T. Maul, P. Laws, L. Naldi, P.D. Ghislain, E. de Jong, S. Mburu, V. Koscielny, E. Massana, I. Kasujee & U. Mrowietz

Poster presented at the 33rd EADV Congress, Amsterdam, the Netherlands

<< < 1 2 3 4 5 6 … 24 > >>